Bio Screening Industry News

Archive for February, 2009

February 25, 2009

Research and Markets: Narrowing the Innovation Gap with Fragment-Based Drug Discovery and Design

Filed under: Press Releases — Editor @ 11:58 pm

Fragment-based drug discovery and design technology could dramatically improve the prospects of identifying suitable development compounds and feed withering clinical pipelines. These technologies have already generated several interesting compounds. If successful, fragment-based design could make a significant difference in the productivity of drug discovery programs and help to lower their cost.

Scope:

  • Fragment-based discovery and design: evolution of compound screening, Lipinski’s Rules, Rule of Five, Rule of Three, the Golden Ratios, low-molecular-weight fragments.
  • Screening methods: computational, biological, X-ray crystallography, nuclear magnetic resonance spectroscopy, surface plasmon resonance.
  • Specialist companies: Astex Therapeutics, Evotec, Graffinity Pharmaceuticals, Locus Pharmaceuticals, Plexxikon, SGX Pharmaceuticals, Sunesis Pharmaceuticals, Vernalis, ZoBio.
  • Outlook: Development compounds, fee-for-service, exploring novel chemotypes.

Company Profiles:

  • Astex Therapeutics
  • Evotec
  • Graffinity Pharmaceuticals
  • Locus Pharmaceuticals
  • Plexxikon
  • SGX Pharmaceuticals
  • Sunesis Pharmaceuticals
  • Vernalis
  • ZoBio

BioFocus DPI Extends Drug Discovery Collaboration with Lilly Drug Discovery & Development

BioFocus DPI has extended its drug discovery agreement with Eli Lilly and Company until end 2009. Under the terms of the agreement, BioFocus DPI will identify active compounds by screening of Lilly’s library compounds.

The agreement extension announced today builds on the successful collaboration begun in March 2005. BioFocus DPI has been working with Lilly on discovering new compounds that target specific cellular signal transduction pathways. With this agreement, Lilly secures continued access to BioFocus DPI’s screening and biology expertise to identify new potential target compounds.

‘We are pleased to extend this collaboration with Lilly into its fourth year,’ said Dr. Chris Newton, Senior VP, BioFocus DPI. ‘It is satisfying to know that BioFocus DPI’s drug discovery research consistently meets the standards of large pharma companies such as Lilly and that we are successful in these long term collaborative relationships.’

February 18, 2009

European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos

ST. LOUIS, Mo.–(BUSINESS WIRE)–Tripos™, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license Tripos’ Themis™ and Surflex-Dock™ software to support their efforts in Chemical Biology. According to Dr. Joe Lewis, Head of the Chemical Biology Core Facility, a collaboration between EMBL, the DKFZ [German Cancer Research Center, Heidelberg] and the University of Heidelberg to provide the infrastructure and expertise to enable small molecule development to research groups at these institutions. “Anytime we can reduce the amount of time it takes to advance our drug discovery efforts, we are very pleased. Tripos’ Surflex-Dock, and new Themis product have enabled us to do exactly that.”

In a benchmark study at EMBL, Surflex-Dock was installed on EMBL’s Linux Grid of 1,400 CPUs. Five million structures of EMBL’s virtual database of commercially available compounds were then docked into a binding site of a project’s receptor structure. The computation was completed in about two days and yielded a promising pool of candidates for experimental testing.

“Virtual screening has become a key technique in Chemical Biology to identify small molecules as tool compounds to help address biological questions. Our testing of Surflex-Dock’s capabilities in this area convinced us that its high speed and accuracy will enable us to quickly find the most promising compounds,” said Dr. Lewis.

Dr. Lewis added, “In first experiments performed at EMBL, Tripos’ Themis already provided interesting new chemical ideas contributing to new drug discovery projects, so in parallel, the Themis technology will enable us to search vast chemical fragment space, as composed and implemented into the Themis database by our medicinal chemists.”

“The decision by the European Molecular Biology Laboratory to select our new Themis technology together with Surflex-Dock is very significant,” said Jim Hopkins, Tripos’ Chief Executive Officer. He added, “The vigorous EMBL study demonstrated that the powerful combination of these two Tripos offerings can effectively enhance the success of discovery efforts.”

February 17, 2009

Pittcon 2009 Exposition Expected to Showcase Latest Innovations

Filed under: North America, USA and Canada, Events, Press Releases — Editor @ 3:08 am

Pittsburgh, PA, USA - The Pittcon 2009 Exposition, which takes place March 8-13, McCormick Place South, Chicago, Illinois will showcase 1,000  exhibitors that manufacture, distribute, and market products for laboratory science and offer turn key services and solutions to laboratories in the industrial, academic, and government sectors. The Exposition will highlight the latest analytical and spectroscopic technologies and innovations for areas including, but not limited to bioanalytical chemistry, pharmaceutical science and drug discovery chemistry, nanotechnology, environmental analysis, forensics, food analysis, and homeland security.

The Exposition is international in scope with approximately 19% of the exhibiting companies headquartered in a variety of countries including Australia, Austria, Canada, China, France, Germany, Italy, Japan, Netherlands, and the United Kingdom.  The 673,000 square foot exposition floor will include 2,244 booths, 43 seminar rooms, 2 complimentary mixers, and 4 specialized areas-New Exhibitor, Life Sciences, Laboratory Informatics, and  the Green Corner, which is new this year, features exhibitors who offer environmental-friendly products and services.  This year, Pittcon will be welcoming 122 new exhibitors which can be viewed at www.pittcon.org.

When asked to comment about the value of the Pittcon 2009 Exposition to conferees, Exposition Chairman Penny Gardner replied, “We believe Pittcon is a unique opportunity for conferees, as well as exhibitors, because it offers such a valuable learning experience.    It is the ideal venue to get a look at all the latest equipment, network with suppliers, interact with technical personnel, and make new vendor contacts-all in one place.”

February 14, 2009

Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers

LA Jolla, CA—Fruit flies and humans share most of their genes, including 70 percent of all known human disease genes. Taking advantage of this remarkable evolutionary conservation, researchers at the Salk Institute for Biological Studies transformed the fruit fly into a laboratory model for an innovative study of gliomas, the most common malignant brain tumors.

“Gliomas are a devastating disease but we still know very little about the underlying disease process,” explains John B. Thomas, Ph.D., a professor in the Molecular Neurobiology Laboratory and senior author of the study, which is published in the current edition of the Public Library of Science Genetics. “We can now use the power of Drosophila genetics to uncover genes that drive these tumors and identify novel therapeutic targets, which will speed up the development of effective drugs.”

Better models for research into human gliomas are urgently needed. Last year alone, about 21,000 people in this country were diagnosed with brain and nervous system cancers, Senator Edward M. Kennedy the most famous among them. About 77 percent of malignant brain tumors are gliomas and their prognosis is usually bleak. While they rarely spread to elsewhere in the body, cancerous glial cells quickly infiltrate the brain and grow rapidly, which renders them largely incurable even with current therapies.

Gliomas originate in brain cells known as “glia” and are categorized into subtypes based on how aggressive they appear, with glioblastoma being the most common and most aggressive form of glioma. Their diversity is mirrored by the number of different signaling pathways involved in the generation of these tumors, yet aggressive gliomas all seem to have one thing in common: Most, if not all human glioblastomas carry mutations that activate the EGFR-Ras and PI-3K signaling pathways. Such mutations are also thought to play a key role in developing drug resistance.

“Fruit flies possess homologs of many relevant human genes including EGFR, Ras, and PI-3K,” explains postdoctoral researcher and first author Renee Read, who spearheaded the project. “We developed the Drosophila model to figure out how these genes specifically regulate brain tumor pathogenesis and to discover new ways to attack these tumors.”

When Read activated both signaling pathways specifically in glia in genetically engineered fruit flies, she found that, just as in the mammalian brain, activation of the EGFR-Ras and PI-3K pathways gave rise to rapidly dividing, invasive cells that created tumor-like growths in the fly brain, mimicking the human disease.

“Once I had verified that the fly tumors share key aspects with human gliomas, I could use the model to screen for new genes that are involved in disease process and compare them to the genes that were found as part of The Cancer Genome Atlas’ glioblastoma initiative,” explains Read.

Glioblastoma is one of the first cancers studied by The Cancer Genome Atlas research network, whose goal is to accelerate understanding of the molecular basis of cancer through the application of modern genome characterization technologies such as large-scale genome sequencing.

Like most cancers, gliomas arise from changes in a person’s DNA that accumulate over a lifetime but sorting changes with wide-ranging impacts from innocent bystanders has been a challenge. “While these initiatives give us big lists of altered genes they don’t tell us much about which ones are really important,” says Read. “Addressing this question in mouse models or patient studies is extremely expensive and time-consuming. In flies, I can test hundreds of genes every week.”

The Salk researchers are now using their fly model to search for genes and drugs that might block EGFR/PI-3K-associated brain tumors. The drug tests are being done in collaboration with co-authors professor Webster Cavenee, Ph.D., and associate professor Frank Furnari, Ph.D., both experts in human brain tumor biology at the Ludwig Institute for Cancer Research at the University of California, San Diego.

The researchers are hoping that through their combined efforts new discoveries from the fly model can be rapidly translated into mouse and human brain tumor studies and lead to development of new therapies for this deadly cancer.

February 12, 2009

Ligand Pharmaceuticals Inc. (LGND) Enters into Screening Agreement with Trevena

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - News) and Trevena Inc. today announced the initiation of a joint research and license alliance to screen targets using Trevena’s novel biological platform against Ligand’s combinatorial library of compounds, to identify active compounds with potential for development as novel G-protein coupled receptor (GPCR) therapeutics.

Under the terms of the agreement, Trevena has been granted exclusive worldwide rights to sublicense active compounds resulting from the collaboration. Ligand expects to screen 24 targets over two years and receive payments triggered by a tiered screening paradigm for each target.

“We are delighted to enter into this collaboration that allows us to generate cash flow from the combinatorial chemistry technology we gained through our acquisition of Pharmacopeia,” said John L. Higgins, President and Chief Executive Officer of Ligand. “Working closely with the Trevena team, we hope to rapidly identify and advance novel drug candidates using their unique insight into GPCR signaling pathways.”

Maxine Gowen, President and CEO of Trevena said, “We are excited to work with these exceptional scientists and get access to this proven chemistry platform. We believe that this collaboration will accelerate our drug discovery efforts and the validation of our biological platform.”

About Trevena, Inc.

Trevena, Inc. is a Philadelphia-based drug discovery company focused on developing pharmaceutical products targeting GPCRs. Pharmaceutical products that target GPCRs represent up to 40% of marketed drugs today. Trevena’s drug discovery platform, licensed from Duke University Medical Center, is based on extensive research from the laboratories of scientists Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. The company’s drug discovery portfolio is currently focused on programs for cardiovascular and CNS indications. Trevena, Inc. is privately held. (www.trevenainc.com)

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases and anemia. Ligand’s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology. In December 2008, we acquired Pharmacopeia in a transaction that provides Ligand rights to numerous collaborations with pharmaceutical companies, pipeline programs and the world’s largest combinatorial chemistry library.

Powered by WordPress